Publication & Citation Trends
Publications
0 total
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials OA
Cited by 8
Semantic Scholar
Long‐term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two‐year results from a Phase III double‐blind, randomized controlled trial
Cited by 10
Semantic Scholar
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study OA
Cited by 15
Semantic Scholar
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data OA
Cited by 82
Semantic Scholar
25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year
Cited by 1
Semantic Scholar
14190 Treatment with secukinumab of severe plaque psoriasis in pediatric patients: Study design and baseline characteristics of a double-blind study
Cited by 0
Semantic Scholar
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial OA
Cited by 87
Semantic Scholar
Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment OA
Cited by 1
Semantic Scholar
Research Topics
Bone health and treatments
(22)
Bone health and osteoporosis research
(20)
Psoriasis: Treatment and Pathogenesis
(13)
Autoimmune and Inflammatory Disorders Research
(9)
Bone and Joint Diseases
(9)
Affiliations
Délégation Paris 5
Roche (Switzerland)
Novartis (Switzerland)
The University of Sydney
University of Liège